⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242266 | 1.00 | — | — | |
| SCHEMBL5388393 | 1.00 | — | — | |
| SCHEMBL10517356 | 0.97 | CYP1A2 (0.59) | — | |
| SCHEMBL10517369 | 0.97 | CYP1A2 (0.59) | — | |
| SCHEMBL2810164 | 0.97 | CYP1A2 (0.59) | — | |
| Ammonia Solution, Strong SCHEMBL10942345 | 0.97 | — | — | |
| SCHEMBL10400548 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL10948146 | 0.97 | CYP1A2 (0.59) | — | |
| SCHEMBL10399513 | 0.97 | — | — | |
| SCHEMBL10940546 | 0.97 | CYP1A2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7252202-A | — | — | None | — | — | JP | disclosed |
| JP-5255243-A | — | — | None | — | — | JP | disclosed |
| EP-4334324-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-109928971-B | Aryl substituted aminotetrahydropyrans and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116209438-A | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | 锐新医药公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-03-30 | — | — | US | disclosed |
| WO-2022235866-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-114980976-A | Covalent RAS inhibitors and uses thereof | 锐新医药公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021108683-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| JP-H07252202-A | METHOD FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID DERIVATIVE | NIPPON STEEL CORP | 1995-10-03 | — | — | JP | disclosed |
| JP-H05255243-A | AZIRIDINE-2-CARBOXYLIC ACID DERIVATIVE AND ITS PRODUCTION | NIPPON STEEL CORP | 1993-10-05 | — | — | JP | disclosed |